Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-100.71%
↓ 655% below average
Average (39q)
18.16%
Historical baseline
Range
High:2479.93%
Low:-1196.30%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -100.71% |
| Q2 2025 | 2479.93% |
| Q1 2025 | 91.45% |
| Q4 2024 | 2.90% |
| Q3 2024 | -43.75% |
| Q2 2024 | -20.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | -33.33% |
| Q3 2023 | -100.00% |
| Q2 2023 | 55.88% |
| Q1 2023 | -30.77% |
| Q4 2022 | -36.84% |
| Q3 2022 | 72.86% |
| Q2 2022 | -1196.30% |
| Q1 2022 | 29.41% |
| Q4 2021 | -53.31% |
| Q3 2021 | -123.76% |
| Q2 2021 | 138.89% |
| Q1 2021 | 49.53% |
| Q4 2020 | -57.35% |
| Q3 2020 | -423.81% |
| Q2 2020 | 110.94% |
| Q1 2020 | 33.79% |
| Q4 2019 | -301.39% |
| Q3 2019 | 127.27% |
| Q2 2019 | 28.26% |
| Q1 2019 | -127.16% |
| Q4 2018 | 78.46% |
| Q3 2018 | -44.06% |
| Q2 2018 | 63.19% |
| Q1 2018 | -145.97% |
| Q4 2017 | -5.78% |
| Q3 2017 | -53.09% |
| Q2 2017 | 46.71% |
| Q1 2017 | -22.91% |
| Q4 2016 | 25.80% |
| Q3 2016 | -255.19% |
| Q2 2016 | 391.36% |
| Q1 2016 | 68.20% |
| Q4 2015 | 6.94% |